Anavex Life Sciences Corp. (AVXL) NASDAQ
2.79
-0.195(-6.54%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Anavex Life Sciences Corp.
Address
51 West 52nd Street
New York City, NY 10019
United States of America (the)
Phone
844 689 3939
Website
Sector
Healthcare
Industry
Biotechnology
Employees
42
First IPO Date
August 02, 2006
Key Executives
| Name | Title | Pay | Year Born |
| Christopher U. Missling | President, Chief Executive Officer, Secretary & Director | 876,085 | 1966 |
| Terrie Kellmeyer | Interim Chief Executive Officer | 0 | N/A |
| Sandra Boenisch | Principal Financial Officer & Treasurer | 247,070 | 1981 |
| Clint Tomlinson | Vice President of Corporate | 0 | N/A |
| Adebayo Laniyonu | Senior Vice President of Nonclinical Development | 0 | N/A |
| Juan Carlos Lopez-Talavera | Senior Vice President & Head of Research and Development | 0 | N/A |
| Kun Jin | Vice President & Head of Biostatistics | 0 | N/A |
| Wolfgang Liedtke | Senior VP & Global Head of Neurology | 0 | N/A |
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
